Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes

Molecular Therapy

Volumn 15, Issue 4, 2007, Pages 792-800

  Li, Hua ^a   Murphy, Samuel L ^b   Giles Davis, Wynetta ^a   Edmonson, Shyrie ^b,c   Xiang, Zhiquan ^a   Li, Yan ^a   Lasaro, Marcio O ^a   High, Katherine A ^b,c   Ertl, Hildegund C J ^a  

^a WISTAR INSTITUTE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; INTERLEUKIN 2 RECEPTOR ALPHA; LIVER ENZYME; NEUTRALIZING ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 9; TRANSCRIPTION FACTOR FOXP3;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DESTRUCTION; CONTROLLED STUDY; EFFECTOR CELL; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HEMOPHILIA B; LIVER CELL; LONGEVITY; LYMPHOCYTE DEPLETION; LYMPHOID TISSUE; MALE; MOUSE; NONHUMAN; PROMOTER REGION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID;

ADOPTIVE TRANSFER; ANIMALS; CAPSID; CD8-POSITIVE T-LYMPHOCYTES; DEPENDOVIRUS; FACTOR IX; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA B; HEPATOCYTES; HUMANS; LYMPHOCYTE DEPLETION; MALE; MICE; MICE, INBRED BALB C; MICE, SCID; TRANSDUCTION, GENETIC;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MIRIDAE; MUS;

EID: 33947196295     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300090     Document Type: Article

References (26)

1. Manno, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M and Rasko, JJ et al. (2006). Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347.
2. Snyder, RO, Miao, C, Meuse, L, Tubb, J, Donahue, BA and Lin, HF et al. (1999). Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 5: 64-70.
3. Mount, JD, Herzog, RW, Tillson, DM, Goodman, SA, Robinson, N and McCleland, ML et al. (2002). Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 99: 2670-2676.
4. Nathwani, AC, Davidoff, AM, Hanawa, H, Hu, Y, Hoffer, FA and Nikanorov, A et al. (2002). Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood 100: 1662-1669.
5. Sabatino, DE, Mingozzi, F, Hui, DJ, Chen, H, Colosi, P and Ertl, HC et al. (2005). Identification of mouse AAV capsid-specific CD8+ T cell epitopes. Mol Ther 12: 1023-1033.
6. Fitzgerald, JC, Gao, GP, Reyes-Sandoval, A, Pavlakis, GN, Xiang, ZQ and Wlazlo, AP et al. (2003). A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 170: 1416-1422.
7. Koeberl, DD, Alexander, IE, Halbert, CL, Russell, DW and Miller, AD (1997). Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci USA 94: 1426-1431.
8. Flotte, TR (2006). New AAV serotypes may broaden the therapeutic pipeline to human gene therapy. Mol Ther 13: 1-2.
9. Suvas, S, Kumaraguru, U, Pack, CD, Lee, S and Rouse, BT (2003). CD4+CD25+T cells regulate virus-specific primary and memory CD8+ T cell responses. J Exp Med 198: 889-901.
10. Dobrzynski, E, Fitzgerald, JC, Cao, O, Mingozzi, F, Wang, L and Herzog, RW (2006). Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells. Proc Natl Acad Sci USA 103: 4592-4597.
11. Mingozzi, F, Liu, YL, Dobrzynski, E, Kaufhold, A, Liu, JH and Wang, Y et al. (2003). Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 111: 1347-1356.
12. Yang, Y, Nunes, FA, Berencsi, K, Furth, EE, Gonczol, E and Wilson, JM (1994). Cellular immunity to viral antigens limits E1-deleted Ades for gene therapy. Proc Natl Acad Sci USA 91: 4407-4411.
13. Yang, Y, Ertl, HC and Wilson, JM (1994). MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant Ades. Immunity 1: 433-442.
14. Schulick, AH, Vassalli, G, Dunn, PF, Dong, G, Rade, JJ and Zamarron, C et al. (1997). Established immunity precludes Ad-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest 99: 209-219.
15. Takahashi, H, Hirai, Y, Migita, M, Seino, Y, Fukuda, Y and Sakuraba, H et al. (2002). Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc Natl Acad Sci USA 99: 13777-13782.
16. Walsh, CE and Chao, H (2002). Parvovirus-mediated gene transfer for the haemophilias. Haemophilia 8 (Suppl 2): 60-67.
17. Arruda, VR, Schuettrumpf, J, Herzog, RW, Nichols, TC, Robinson, N and Lotfi, Y et al. (2004). Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood 103: 85-92.
18. Greelish, JP, Su, LT, Lankford, EB, Burkman, JM, Chen, H and Konig, SK et al. (1999). Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med 5: 439-443.
19. Snyder, RO, Spratt, SK, Laqarde, C, Bohl, D, Kaspar, B and Sloan, B et al. (1997). Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum Gene Ther 8: 1891-1900.
20. Fields, PA, Kowalczyk, DW, Arruda, VR, Armstrong, E, McCleland, ML and Hagstrom, JN et al. (2000). Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther 1: 225-235.
21. Jooss, K and Chirmule, N (2003). Immunity to adenovirus and adeno-associated viral vectors: Implications for gene therapy. Gene Ther 10: 955-963.
22. La, S, Kim, J, Kwon, BS and Kwon, B (2002). Herpes simplex virus type 1 glycoprotein D inhibits T-cell proliferation. Mol Cell 14: 398-403.
23. Quenelle, DC, Collins, DJ, Marciani, DJ and Kern, ER (2006). Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2. Vaccine 24: 1515-1522.
24. Chen, W, Masterman, KA, Basta, S, Haeryfar, SM, Dimopoulos, N and Knowles, B et al. (2004). Cross-priming of CD8+ T cells by viral and tumor antigens is a robust phenomenon. Eur J Immunol 34: 194-199.
25. Vandenberghe, LH, Wang, L, Somanathan, S, Zhi, Y, Figueredo, J and Calcedo, R et al. (2006). Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat Med 12: 967-971.
26. Grimm, D, Zhou, S, Nakai, H, Thomas, CE, Storm, TA and Fuess, S et al. (2003). Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 102: 2412-2419.